NEW CANAAN, Conn., Dec. 15, 2025 /PRNewswire/ -- FlyteHealth, a leader in precision cardio-kidney- metabolic care, today announced that it has been featured by CMS for eCKM management in advance of the upcoming ACCESS Model, a 10-year Medicare payment demonstration beginning July 1, 2026. Advancing Chronic Care with Effective, Scalable Solutions areas of Hypertension, Dyslipidemia, Obesity, central adiposity, and Prediabetes represent the upstream drivers of heart disease, stroke, kidney failur

Statewide Practice Expands Clinical Team in Marion County FORT MYERS, Fla., Dec. 15, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that board-certified medical oncologist and hematologist Sarath Katragadda, MD, MSc has joined its team of cancer experts in Marion County. Dr. Katragadda has specialized clinical interest in genitourinary, gastrointestinal, and breast cancers. He is caring for patients at the FCS Ocala Cancer Center, 4945 SW 4

VIRGINIA BEACH, Va. and CHARLESTON, S.C., Dec. 15, 2025 /PRNewswire/ -- LifeNet Health, a global leader in regenerative medicine, has acquired Tissue Testing Technologies LLC (T3), a biotechnology company specializing in biopreservation. T3 's advanced proprietary technologies and services preserve living cells and tissues for clinical and research applications, ensuring the quality and impact of life-saving therapies. This acquisition enhances LifeNet Health's ability to improve patient outcome

NEW YORK, Dec. 15, 2025 /PRNewswire/ -- A new report by Treatment Action Group (TAG) warns that a key ingredient in several vaccines of global health importance may face critical supply bottlenecks in the coming years unless governments, funders, and pharmaceutical companies increase market transparency, security, and competitiveness. From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first-of-its-kind analysis of t

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration with Daiichi Sankyo (TSE: 4568) that aims to accelerate biomarker discovery and optimize translational research by integrating multiple AI-powered Lunit SCOPE

Combining breakthrough blood-based test with same-week access to board-certified hepatologists in all 50 states IRVINE, Calif., Dec. 15, 2025 /PRNewswire/ -- Helio Genomics ("Helio" or "the Company"), an AI-driven techbio company specializing in diagnostics technology for cancer detection, today announces a strategic partnership with LiverRight®, the National Virtual Clinic for Liver Disease in Adults. The partnership integrates Helio's LiverTrace™ blood-based liver cancer test with LiverRight's

Kid-friendly, orange-flavored strips make dosing simple, precise, and enjoyable for children ages 2–9 BURLINGTON, Vt., Dec. 15, 2025 /PRNewswire/ -- Calmour Health announced the launch of its breakthrough Children's Acetaminophen Quick-Dissolving Oral Strips, bringing safe, mess-free, and stress-free fever and pain relief to families. Designed specifically for children ages 2 to 9, each thin strip dissolves instantly on the tongue—no water, no measuring, and no struggle required. Continue Readin

PHILADELPHIA, Dec. 15, 2025 /PRNewswire/ -- Kang Haggerty LLC is proud to announce that it represented the whistleblower in a False Claims Act (FCA) case that resulted in a $2 million settlement with Recovery Centers of America (RCA). The settlement resolves allegations that RCA mishandled controlled substances in violation of the Controlled Substances Act (CSA) and billed the government for inadequate treatment services in violation of the FCA. United States Attorney David Metcalf announced the

SAN JOSE, Calif., Dec. 15, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed the transfer of the Investigational New Drug application ("IND") for its breast cancer vaccine from Cleveland Clinic. Anixa is now the trial sponsor for future development of its breast cancer vaccine. The transfer of the IND is a natural and planned step in the progresso

Regulatory clearance enables launch of the MAVERICS Coronary Revascularization Study, advancing evaluation of the Company's next-generation synthetic small-diameter bypass graft. MINNEAPOLIS, Dec. 15, 2025 /PRNewswire/ -- Medical 21, Inc., a private medical technology company developing a novel regenerative small-diameter coronary bypass graft, today announced that it has received regulatory approval in Spain under the European Union Medical Device Regulation (EU MDR) to initiate the Company's f